Life Sciences

In January 2017, the FDA published guidance that adopted a naming convention that attaches a distinguishing suffix to the proper names of both originator and biosimilar biological products. The gui...

We are pleased to highlight some of our representative intellectual property-related client successes and publications over the past year that might be relevant to your business success in the coming ...

Patent litigation can often be a costly, lengthy, and resource-intensive endeavor. Recognizing the frequency, duration, and potentially debilitating effects of patent litigation, Congress passed th...

In November 2016, the U.S. Food and Drug Administration issued a final guidance on medical device reporting for manufacturers ("Final MDR Guidance"). The Final MDR Guidance addresses: (1) manufacturer...

The holding pattern for the telemedicine/telehealth industry (referred to generally in this article as “telemedicine”) appears to be lifted with a stay in the Texas Medical Board (“TMB”) vs. Teladoc l...

While overall healthcare and biotech public M&A activity declined in 2016 relative to 2015, there were still a significant number of large transactions announced in 2016 such as Pfizer’s $14 billio...

Initial public offerings in the United States for biotechnology and medical device companies remained resilient in 2016, based on research showing 31 deals consummated for aggregate gross proceeds ...

This month's newsletter features articles about the CMS and MACRA, Healthcare employers and why they should evaluate exempt workers, the next steps for Telemedicine in Texas, and the Federal Trade ...

Earlier this year, we wrote about the spotlight on food labeling in 2016. Halfway through the year, the changes to food and beverage labeling show no signs of slowing down. The U.S. Food and Drug A...

Support for telemedicine and telehealth services continues to gain traction in Texas, as evidenced by the Texas Health and Human Services Commission's willingness to consider the use of telemedicine s...